Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (157)	11/19/2005 8:24:12 AM
From: rkrw	Respond to of 332

I'm far less of an expert. Birds eye view, I think the primary endpoint is a 20% reduction in events over and above best in class treatment, statins, that seems like an awfully high bar. A good one to play with options? If it works, we're probably talking a triple digit stock, if not even close, maybe close to zero?

To: Miljenko Zuanic who wrote (157)	12/28/2005 3:52:26 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 332

>>Majority, if not all, animal studies were with very high drug dose, so data are irrelevant, imo.<< I ran across the minutes from the 2002 American Chemical Society meeting. During this meeting, Charles Meng, an AGIX scientist, described the research that led to the derivation of 1067 and described the 1-year hypercholesterolemic monkey study. For the hypercholesterolemic monkey study, Meng reported that the 150 mg/kg/day dosage yielded plasma concentrations similar to humans at 280 kg/day (although this is not mentioned in the C. Sundell, P. Somers paper that documents the animal studies). 64.233.167.104